ERBB2 and breast cancer: Meanwhile, patients confronting metastatic BC characterised by both HR positivity and HER2 positivity face varied outcomes contingent upon the specific treatments administered and the distinct characteristics of the cancer, along with a consideration of the 3-year overall survival [32].